Therapeutic effect of ofatumumab in patients with myasthenia gravis: immunoregulation of follicular T helper cells and T helper type 17 cells
IntroductionThis study aimed to study the therapeutic effects of ofatumumab in patients with myasthenia gravis (MG) in addition to the immunomodulatory effects on peripheral follicular T helper (Tfh) cells and T helper type 17 (Th17) cells.MethodsThirty-one patients with anti-acetylcholine receptor...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2023.1278250/full |
| _version_ | 1797396982966255616 |
|---|---|
| author | Shasha Li Shasha Li Zhaoxu Zhang Zunjing Liu |
| author_facet | Shasha Li Shasha Li Zhaoxu Zhang Zunjing Liu |
| author_sort | Shasha Li |
| collection | DOAJ |
| description | IntroductionThis study aimed to study the therapeutic effects of ofatumumab in patients with myasthenia gravis (MG) in addition to the immunomodulatory effects on peripheral follicular T helper (Tfh) cells and T helper type 17 (Th17) cells.MethodsThirty-one patients with anti-acetylcholine receptor (AChR) antibody-positive MG were included in this study. At weeks 0, 1, 2, and 4, an initial dose of 20 mg of ofatumumab was injected subcutaneously, with a 2-month follow-up after completing this first cycle. At baseline, 1 month, and 3 months, we assessed the Quantitative MG (QMG), 15-item MG-Quality of Life (MG-QOL15), and MG-Activities of Daily Living (MG-ADL) scales and measured the frequencies of Tfh, Th17, and B cells and the levels of anti-AChR antibody, IL-6, IL-21, and IL-17 in the peripheral blood.ResultsAt 1 month and 3 months, the QMG, MG-QOL15, and MG-ADL scores were all significantly reduced. At 3 months, doses of prednisone were reduced by an average of 37%. Decreased frequencies of Tfh and Th17 cells, depletion of B cells, and reduced levels of IL-6, IL-21, and IL-17 were all observed at 1 month or 3 months.DiscussionTherefore, the therapeutic effect of ofatumumab could be detected after one cycle of treatment, which was maintained for 2 months. The immunomodulatory effect of ofatumumab during the observation period may involve depletion of B cells, reduction of Tfh and Th17 cells frequencies, and reduced levels of IL-6, IL-21, and IL-17. The findings provide novel data for the potential application of ofatumumab in MG. |
| first_indexed | 2024-03-09T01:03:31Z |
| format | Article |
| id | doaj.art-2fa3db78c442430f969babf591906c44 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-03-09T01:03:31Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-2fa3db78c442430f969babf591906c442023-12-11T12:43:44ZengFrontiers Media S.A.Frontiers in Neurology1664-22952023-12-011410.3389/fneur.2023.12782501278250Therapeutic effect of ofatumumab in patients with myasthenia gravis: immunoregulation of follicular T helper cells and T helper type 17 cellsShasha Li0Shasha Li1Zhaoxu Zhang2Zunjing Liu3Graduate School of Beijing University of Chinese Medicine, Beijing, ChinaDepartment of Neurology, China-Japan Friendship Hospital, Beijing, ChinaDepartment of Neurology, Peking University People's Hospital, Beijing, ChinaDepartment of Neurology, Peking University People's Hospital, Beijing, ChinaIntroductionThis study aimed to study the therapeutic effects of ofatumumab in patients with myasthenia gravis (MG) in addition to the immunomodulatory effects on peripheral follicular T helper (Tfh) cells and T helper type 17 (Th17) cells.MethodsThirty-one patients with anti-acetylcholine receptor (AChR) antibody-positive MG were included in this study. At weeks 0, 1, 2, and 4, an initial dose of 20 mg of ofatumumab was injected subcutaneously, with a 2-month follow-up after completing this first cycle. At baseline, 1 month, and 3 months, we assessed the Quantitative MG (QMG), 15-item MG-Quality of Life (MG-QOL15), and MG-Activities of Daily Living (MG-ADL) scales and measured the frequencies of Tfh, Th17, and B cells and the levels of anti-AChR antibody, IL-6, IL-21, and IL-17 in the peripheral blood.ResultsAt 1 month and 3 months, the QMG, MG-QOL15, and MG-ADL scores were all significantly reduced. At 3 months, doses of prednisone were reduced by an average of 37%. Decreased frequencies of Tfh and Th17 cells, depletion of B cells, and reduced levels of IL-6, IL-21, and IL-17 were all observed at 1 month or 3 months.DiscussionTherefore, the therapeutic effect of ofatumumab could be detected after one cycle of treatment, which was maintained for 2 months. The immunomodulatory effect of ofatumumab during the observation period may involve depletion of B cells, reduction of Tfh and Th17 cells frequencies, and reduced levels of IL-6, IL-21, and IL-17. The findings provide novel data for the potential application of ofatumumab in MG.https://www.frontiersin.org/articles/10.3389/fneur.2023.1278250/fullmyasthenia gravisofatumumabfollicular T helper cellsT helper type 17 cellsB cells depletion |
| spellingShingle | Shasha Li Shasha Li Zhaoxu Zhang Zunjing Liu Therapeutic effect of ofatumumab in patients with myasthenia gravis: immunoregulation of follicular T helper cells and T helper type 17 cells Frontiers in Neurology myasthenia gravis ofatumumab follicular T helper cells T helper type 17 cells B cells depletion |
| title | Therapeutic effect of ofatumumab in patients with myasthenia gravis: immunoregulation of follicular T helper cells and T helper type 17 cells |
| title_full | Therapeutic effect of ofatumumab in patients with myasthenia gravis: immunoregulation of follicular T helper cells and T helper type 17 cells |
| title_fullStr | Therapeutic effect of ofatumumab in patients with myasthenia gravis: immunoregulation of follicular T helper cells and T helper type 17 cells |
| title_full_unstemmed | Therapeutic effect of ofatumumab in patients with myasthenia gravis: immunoregulation of follicular T helper cells and T helper type 17 cells |
| title_short | Therapeutic effect of ofatumumab in patients with myasthenia gravis: immunoregulation of follicular T helper cells and T helper type 17 cells |
| title_sort | therapeutic effect of ofatumumab in patients with myasthenia gravis immunoregulation of follicular t helper cells and t helper type 17 cells |
| topic | myasthenia gravis ofatumumab follicular T helper cells T helper type 17 cells B cells depletion |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2023.1278250/full |
| work_keys_str_mv | AT shashali therapeuticeffectofofatumumabinpatientswithmyastheniagravisimmunoregulationoffollicularthelpercellsandthelpertype17cells AT shashali therapeuticeffectofofatumumabinpatientswithmyastheniagravisimmunoregulationoffollicularthelpercellsandthelpertype17cells AT zhaoxuzhang therapeuticeffectofofatumumabinpatientswithmyastheniagravisimmunoregulationoffollicularthelpercellsandthelpertype17cells AT zunjingliu therapeuticeffectofofatumumabinpatientswithmyastheniagravisimmunoregulationoffollicularthelpercellsandthelpertype17cells |